Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Casper F. Nielsen
Observed names:
C.F. Nielsen,
Casper Nielsen,
Casper Nielsen C,
Nielsen, C
Institutions:
UCL Queen Square Institute of Neurology,
University College London
Observed institutions:
London School of Hygiene & Tropical Medicine,
National Hospital for Neurology and Neurosurgery,
UCL Queen Square Institute of Neurology,
University College London,
Middlesex University London
ORCID:
0000-0002-7112-9595
Observed ORCID:
0000-0002-7112-9595
OpenAlex ID:
A5028255509
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
2014
·
Jeremy Chataway
, Nadine Schuerer
, et al.
·
The Lancet
·
444
PDF
Automatic morphometry in Alzheimer's disease and mild cognitive impairment
2011
·
Rolf A. Heckemann
, Shiva Keihaninejad
, et al.
·
NeuroImage
·
135
PDF
Volume changes in Alzheimer’s disease and mild cognitive impairment: cognitive associations
2009
·
and the Alzheimer’s Disease Neuroimaging Initiative
, Matthew C. Evans
, et al.
·
European Radiology
·
121
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial
2021
·
Patrick Gavin Kehoe
, Nicholas Turner
, et al.
·
The Lancet Neurology
·
57
PDF
Comparison of phantom and registration scaling corrections using the ADNI cohort
2009
·
Matthew J. Clarkson
, Sébastien Ourselin
, et al.
·
NeuroImage
·
54
Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer’s Disease
2015
·
Gerald Novak
, Nick Fox
, et al.
·
Journal of Alzheimer s Disease
·
53
Effects of viewing and orientation on path following in a medical teleoperation environment
2002
·
P.J. Passmore
, C.F. Nielsen
, et al.
·
IEEE Virtual Reality (VR)
·
19
The MS-STAT trial: high dose simvastatin demonstrates neuroprotection without immune-modulation in secondary progressive multiple sclerosis (SPMS) - a phase II trial
2012
·
Chataway, J
, Alsanousi, A
, et al.
·
UCL Discovery (University College London)
·
9
Losartan to slow the progression of mild-to-moderate Alzheimer’s disease through angiotensin targeting: the RADAR RCT
2021
·
Patrick G Kehoe
, Nicholas Turner
, et al.
·
Efficacy and Mechanism Evaluation
·
7
PDF
THE MS-STAT TRIAL: High Dose Simvastatin Slows Brain Atrophy and Delays Disability in Secondary Progressive Multiple Sclerosis: A Phase II Placebo-Controlled Trial (PL02.001)
2013
·
Jeremy Chataway
, Nadine Schuerer
, et al.
·
Neurology
·
7
A solution to the problem of segmentation near edges using adaptable class-specific representation
2002
·
C.F. Nielsen
, P.J. Passmore
·
Proceedings - International Conference on Pattern Recognition/Proceedings/International Conference on Pattern Recognition
·
3
Achieving accurate colour image segmentation in 2D and 3D with LVQ classifiers and partial adaptable class-specific representation
2002
·
C.F. Nielsen
, P.J. Passmore
·
Proceedings
·
3
P1–352: The rate of clinical progression and brain atrophy is greater with increasing severity of Alzheimer's disease: Results from the volumetric MRI substudies of two phase III trials with bapineuzumab
2013
·
Gerald Novak
, Steven Einstein
, et al.
·
Alzheimer s & Dementia
·
2
PDF
Towards a Robust Path Growing Algorithm for Semi-automatic MRI Segmentation
2001
·
Casper F. Nielsen
, Peter J. Passmore
·
Lecture notes in computer science
·
2
PDF
Smaller baseline brain volume and higher atrophy rate over two years is associated with poorer clinical outcomes: post hoc analysis of the MS-STAT trial in Secondary Progressive MS (P7.259)
2015
·
Jeremy Chataway
, Jennifer Nicholas
, et al.
·
Neurology
·
1
P1–335: The impact of gradient field distortion on the calculation of brain atrophy in Alzheimer's disease, derived from volumetric MRI using the boundary shift integral
2013
·
Steven Einstein
, Sylvain Bouix
, et al.
·
Alzheimer s & Dementia
·
1
PDF
P1–356: Correlation of brain atrophy with clinical progression in mild‐to‐moderate Alzheimer's disease: Results from the volumetric MRI substudies of two phase III trials with bapineuzumab
2013
·
Gerald Novak
, Steven Einstein
, et al.
·
Alzheimer s & Dementia
·
1
A repository of MR morphometry data in Alzheimer's disease and mild cognitive impairment
2011
·
Rolf A. Heckemann
, Shiva Keihaninejad
, et al.
·
IEEE International Symposium on Biomedical Imaging: From Nano to Macro (ISBI)
·
1
Supplementary adverse event details
2021
·
Patrick G. Kehoe
, Nicholas Turner
, et al.
Details of cognitive assessments, measures of daily life and quality of life
2021
·
Patrick G. Kehoe
, Nicholas Turner
, et al.
Introduction (including scientific background and explanation of rationale)
2021
·
Patrick G. Kehoe
, Nicholas J. Turner
, et al.
P3–095: Comparison of accelerated and nonaccelerated MRI in ADNI: Effects on measures of brain and ventricular volumes and rates of atrophy
2013
·
Kelvin Leung
, Casper Nielsen
, et al.
·
Alzheimer s & Dementia
IC‐P‐150: Comparison of accelerated and nonaccelerated MRI in ADNI: Effects on measures of brain and ventricular volumes and rates of atrophy
2013
·
Kelvin Leung
, Casper Nielsen
, et al.
·
Alzheimer s & Dementia
IC‐P‐185: The impact of gradient field distortion on the calculation of brain atrophy in Alzheimer's disease, derived from volumetric MRI using the boundary shift integral
2013
·
Steven Einstein
, Sylvain Bouix
, et al.
·
Alzheimer s & Dementia
Automated and consistent brain atrophy estimation using boundary shift integral in longitudinal MRI study
2011
·
K K Leung
, Gerard R. Ridgway
, et al.
·
UCL Discovery (University College London)
Show more works
View as search
Works count:
38
Citation count:
920
H-index:
8
I10-index:
7
Year
Topic
Type
